|
Target Audience
Psychiatrists
Learning
Objectives
1. Based on relevant guidelines, you will be able to consider and explain the
benefits and risks of stimulant use in adolescent and adult patients—with and
without preexisting cardiovascular conditions—to create an optimized treatment
plan.
2. You will be
able to evaluate the risks for abuse, misuse, and diversion of medications for
ADHD and to discuss and apply this information when considering treatment
options for your adolescent and adult patients with ADHD.
Accreditation/Designation Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Veritas Institute for
Medical Education, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians
should only claim credit commensurate with the extent of their participation in
the activity.
Financial
Disclosure Statements
In accordance with the ACCME’s Standards for Commercial Support, all CME
providers are required to disclose to the activity audience the relevant
financial relationships of the planners, teachers, and authors involved in the
development of CME content. An individual has a relevant financial relationship
if he or she has a financial relationship in any amount occurring in the last 12
months with a commercial interest whose products or services are discussed in
the CME activity content over which the individual has control. Disclosures are
as follows:
James J. McGough, MD―Eli Lilly and Company; McNeil Consumer and Specialty
Products, a Division of McNeil-PPC, Inc; Novartis Pharmaceuticals Corporation;
Shire (grant/research support, speakers bureau, and/or consultant).
Timothy E. Wilens,
MD―Abbott Laboratories, Cephalon Inc, Eli Lilly and
Company, Janssen Pharmaceutica Products LP, National Institute of Mental Health,
National Institute on Drug Abuse, Neurosearch, Novartis Pharmaceuticals
Corporation, Ortho-McNeil, Pfizer Inc, Shire (grant/research support, speakers
bureau, and/or consultant).
The staff of Veritas
Institute for Medical Education, Inc. has nothing to disclose.
Unlabeled Use
Disclosure Statement
Participants are advised that this CME activity will
contain references to unlabeled/unapproved/ investigational uses of
guanfacine, clonidine, methylphenidate, amphetamine
compounds, and atomoxetine.
Method of Participation
Listen to the prerecorded telesymposium and complete the CME Activity Posttest
and Evaluation and the Request for Credit form. You will receive your CME
certificate immediately. This activity is provided free of charge to
participating physicians. |
Safety Issues in
Managing ADHD in
Adolescents Transitioning to Adulthood
James J.
McGough, MD
Release Date: July 2007
Expiration Date: June 30, 2008
Please enter a
valid e-mail address in the space below to access the
CME Activity Posttest and Evaluation and the Request for Credit
form.
 |